http://surgerybook.net/

1991;64(2):229–230.

29. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J

Leukoc Biol 1998;64(1):14–18.

30. Beamer LJ, Carroll SF, Eisenberg D. The BPI/LBP family of proteins: a structural analysis of

conserved regions. Protein Sci 1998;7(4):906–914.

31. Gabay JE, Scott RW, Campanelli D, et al. Antibiotic proteins of human polymorphonuclear

leukocytes. Proc Natl Acad Sci U S A 1989;86(14):5610–5614.

32. Tsung A, Klune JR, Zhang X, et al. HMGB1 release induced by liver ischemia involves Toll-like

receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp

Med 2007;204(12):2913–2923.

33. Chapple IL. Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol

1997;24(5):287–296.

34. Kasahara Y, Iwai K, Yachie A, et al. Involvement of reactive oxygen intermediates in spontaneous

and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood 1997;89(5):1748–1753.

35. Roos D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microbes Infect

2003;5(14):1307–1315.

36. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin

system. Free Radic Biol Med 2001;31(11):1287–1312.

37. Winyard PG, Perret D, Harris G, et al. The role of toxic oxygen species in inflammation with special

reference to DNA damage. In: Whicker JT, Evans SW, eds. Biochemistry of Inflammation. Boston,

MA: Kluwer Academic; 1992.

38. Nohl H. Generation of superoxide radicals as byproduct of cellular respiration. Ann Biol Clin (Paris)

1994;52(3):199–204.

39. Schuchert RD, Billiar TR. Inflammation. In: Greenfield LJ, ed. Surgery: Scientific Principles and

Practice. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.

40. Menshikova EV, Salama G. Cardiac ischemia oxidizes regulatory thiols on ryanodine receptors:

captopril acts as a reducing agent to improve Ca2 +uptake by ischemic sarcoplasmic reticulum. J

Cardiovasc Pharmacol 2000;36(5):656–668.

41. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemiareperfusion injury. Shock 1996;6(2):79–88.

42. Warren J, Ward P, Johnson K. Oxygen radicals as mediators of inflammation. In: Hensen PM,

Murphy RC, eds. Handbook of Inflammation. Vol 6. New York: Elsevier Science Publishers BV; 1989.

43. Burg ND, Pillinger MH. The neutrophil: function and regulation in innate and humoral immunity.

Clin Immunol 2001;99(1):7–17.

44. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in

primary angioplasty. N Engl J Med 2006;354(26):2773–2782.

45. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J

Immunol 2012;189(6):2689–2695.

46. Zawrotniak M, Rapala-Kozik M. Neutrophil extracellular traps (NETs) - formation and implications.

Acta biochimica Polonica 2013;60(3):277–284.

47. Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J

Thromb Haemost 2008;6(3):415–420.

48. Kobayashi SD, Voyich JM, DeLeo FR. Regulation of the neutrophil-mediated inflammatory response

to infection. Microbes Infect 2003;5(14):1337–1344.

49. Burkitt HG, Young B, Heath JW. Wheater’s Functional Histology: A Text and Colour Atlas. 3rd ed.

Edinburgh, UK; Churchill Livingstone; 1993.

50. Ma J, Chen T, Mandelin J, et al. Regulation of macrophage activation. Cell Mol Life Sci

2003;60(11):2334–2346.

51. Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of

inflammatory cells. J Biol Chem 1995;270(20):11703–11706.

52. Kuijpers T, Hakkert B, Knol E, et al. Membrane surface antigen expression on human monocytes:

changes during purification, in vitro activation and transmigration across monolayers of endothelial

cells. In: Furtin RV, ed. Mononuclear Phagocytes: Biology of Monocytes and Macrophages. Boston, MA:

224

http://surgerybook.net/

Kluwer Academic; 1992.

53. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78(6):915–918.

54. de Waal Malefyt R, Yssel H, Roncarolo MG, et al. Interleukin-10. Curr Opin Immunol

1992;4(3):314–320.

55. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol

1997;15:323–350.

56. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med

2004;255(3):320–331.

57. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science

1999;285(5425):248–251.

58. Griffiths GM, The cell biology of CTL killing. Curr Opin Immunol 1995;7(3):343–348.

59. Romagnani S. Understanding the role of Th1/Th2 cells in infection. Trends Microbiol

1996;4(12):470–473.

60. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to

different functional properties. Annu Rev Immunol 1989;7:145–173.

61. Lane PJ, Brocker T. Developmental regulation of dendritic cell function. Curr Opin Immunol

1999;11(3):308–313.

62. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature

1998;392(6673):245–252.

63. Braciale TJ, Morrison LA, Sweetser MT, et al. Antigen presentation pathways to class I and class II

MHC-restricted T lymphocytes. Immunol Rev 1987;98:95–114.

64. Razi-Wolf Z, Freeman GJ, Galvin F, et al. Expression and function of the murine B7 antigen, the

major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci U S A

1992;89(9):4210–4214.

65. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class IIrestricted T lymphocytes. Annu Rev Immunol 1990;8:773–793.

66. Gumperz JE, Parham P. The enigma of the natural killer cell. Nature 1995;378(6554):245–248.

67. Janeway C, Travers P. Immunobiology: the immune system in health and disease. In: Janeway C,

Travers P, eds. Immunobiology: The Immune System in Health and Disease. 3rd ed. 1997.

68. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the

thymus. Nature 1994;372(6501):100–103.

69. Zal T, Volkmann A, Stockinger B. Mechanisms of tolerance induction in major histocompatibility

complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med

1994;180(6):2089–2099.

70. Picker LJ. Control of lymphocyte homing. Curr Opin Immunol 1994;6(3):394–406.

71. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through

LFA-1. Nature 1989;341(6243):619–624.

72. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep

paradigm. Cell 1994;76(2):301–314.

73. Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76(2):275–285.

74. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today

1996;17(3):138–146.

75. Jain J, McCaffrey PG, Miner Z, et al. The T-cell transcription factor NFATp is a substrate for

calcineurin and interacts with Fos and Jun. Nature 1993;365(6444):352–355.

76. Lee KP, Harlan DM, June CH. Role of co-stimulation in the host response to infection. In: Gallin JI,

Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. 3rd ed. Philadelphia, PA:

Lippincott Williams & Wilkins; 1999.

77. Lin MY, Zal T, Ch’en IL, et al. A pivotal role for the multifunctional calcium/calmodulin-dependent

protein kinase II in T cells: from activation to unresponsiveness. J Immunol 2005;174(9):5583–

5592.

78. Broide DH, Hoffman H, Sriramarao P. Genes that regulate eosinophilic inflammation. Am J Hum

Genet 1999;65(2):302–307.

79. Elsner J, Kapp A. Regulation and modulation of eosinophil effector functions. Allergy

225

http://surgerybook.net/

1999;54(1):15–26.

80. Weller PF, Bach DS, Austen KF. Biochemical characterization of human eosinophil Charcot-Leyden

crystal protein (lysophospholipase). J Biol Chem 1984;259(24):15100–15105.

81. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999;51(2):213–340.

82. Slungaard A, Mahoney JR Jr, Thiocyanate is the major substrate for eosinophil peroxidase in

physiologic fluids. Implications for cytotoxicity. J Biol Chem 1991;266(8):4903–4910.

83. Wardlaw AJ, Moqbel R, Kay AB. Eosinophils: biology and role in disease. Adv Immunol

1995;60:151–266.

84. Wedi B, Raap U, Lewrick H, et al. Delayed eosinophil programmed cell death in vitro: a common

feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol

1997;100(4):536–543.

85. Valent P, Schmidt G, Besemer J, et al. Interleukin-3 is a differentiation factor for human basophils.

Blood 1989;73(7):1763–1769.

86. Nilsson G, Cost J, Metcalfke D. Mast cells and basophils. In: Gallin JI, Snyderman R, eds.

Inflammation: Basic Principles and Clinical Correlates. 3rd ed. Philadelphia, PA: Lippincott Williams &

Wilkins; 1999.

87. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77(4):1033–1079.

88. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon

Cytokine Res 2002;22(9):913–922.

89. Marcus A. Platelets: their role in hemostasis, thrombosis, and inflammation. In : Gallin J,

Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. 3rd ed. Philadelphia, PA:

Lippincott Williams & Wilkins; 1999.

90. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood

1997;89(11):3897–3908.

91. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J

Thromb Haemost 2003;1(9):1897–1905.

92. Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell

interactions or a therapeutic opportunity? Prostaglandins 1997;53(2): 107–137.

93. Marcus AJ, Safier LB, Ullman HL, et al. Platelet-neutrophil interactions. (12S)-

hydroxyeicosatetraen-1,20-dioic acid: a new eicosanoid synthesized by unstimulated neutrophils

from (12S)-20-dihydroxyeicosatetraenoic acid. J Biol Chem 1988;263(5):2223–2229.

94. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact

of cytokines. FASEB J 1996;10(10):1147–1158.

95. Colletti LM. Cytokines. In: Greenfield LJ, ed. Surgery: Scientific Principles and Practice. 3rd ed.

Philadelphia, PA: Lippincott Williams & Wilkins; 2001.

96. Thomson A. The Cytokine Handbook. 3rd ed. New York: Academic Press; 1998.

97. Schmidt AM, Yan SD, Yan SF, et al. The biology of the receptor for advanced glycation end

products and its ligands. Biochim Biophys Acta 2000;1498(2–3):99–111.

98. Strieter RM, Lynch JP III, Basha MA, et al. Host responses in mediating sepsis and adult respiratory

distress syndrome. Semin Respir Infect 1990;5(3):233–247.

99. Opal SM, Patrozou E. Translational research in the development of novel sepsis therapeutics:

logical deductive reasoning or mission impossible? Crit Care Med 2009;37(1 suppl):S10–S15.

100. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol 1992;62(1 Pt 2):S3–S10.

101. Bauss F, Droge W, Mannel DN. Tumor necrosis factor mediates endotoxic effects in mice. Infect

Immun 1987;55(7):1622–1625.

102. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte

cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986;323(6083):86–89.

103. Adam-Klages S, Schwandner R, Adam D, et al. Distinct adapter proteins mediate acid versus neutral

sphingomyelinase activation through the p55 receptor for tumor necrosis factor. J Leukoc Biol

1998;63(6):678–682.

104. Tartaglia LA, Ayres TM, Wong GH, et al. A novel domain within the 55 kd TNF receptor signals cell

death. Cell 1993;74(5):845–853.

105. Meager A. Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine

226

http://surgerybook.net/

Growth Factor Rev 1999;10(1):27–39.

106. Chen G, Ward MF, Sama AE, et al. Extracellular HMGB1 as a proinflammatory cytokine. J Interferon

Cytokine Res 2004;24(6):329–333.

107. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory

activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61(1):1–9.

108. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock

during lethal bacteraemia. Nature 1987;330(6149):662–664.

109. Tracey KJ, Lowry SF, Cerami A. Cachectin/TNF mediates the pathophysiological effects of bacterial

endotoxin/lipopolysaccharide (LPS). Prog Clin Biol Res 1988;272:77–88.

110. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping

biological activities. Lab Invest 1987;56(3):234–248.

111. Sims JE, March CJ, Cosman D, et al. cDNA expression cloning of the IL-1 receptor, a member of the

immunoglobulin superfamily. Science 1988;241(4865):585–589.

112. Kuno K, Matsushima K. The IL-1 receptor signaling pathway. J Leukoc Biol 1994;56(5):542–547.

113. Colotta F, Dower SK, Sims JE, et al. The type II ‘decoy’ receptor: a novel regulatory pathway for

interleukin 1. Immunol Today 1994;15(12):562–566.

114. Bevilacqua MP, Schleef RR, Gimbrone MA Jr, et al. Regulation of the fibrinolytic system of

cultured human vascular endothelium by interleukin 1. J Clin Invest 1986;78(2):587–591.

115. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675–

705.

116. Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/chemokine receptor nomenclature. J

Interferon Cytokine Res 2002;22(10):1067–1068.

117. Bacon KB, Greaves DR, Dairaghi DJ, et al. The expanding universe of C, CX3C, and CC chemokines.

In: Thomson A, ed. The Cytokine Handbook. 3rd ed. New York: Academic Press; 1998.